Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8459-8468

  Zhang, Yuan ^a,b   Peng, Lei ^a   Mumper, Russell J ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Apoptosis; C Myc siRNA; Calcium phosphate nanoparticle; Gemcitabine monophosphate; Proliferation

Indexed keywords

C-MYC SIRNA; CALCIUM PHOSPHATE NANOPARTICLES; CHEMOTHERAPEUTIC AGENTS; INHIBITION OF TUMOR GROWTH; MONOPHOSPHATES; NON SMALL CELL LUNG CANCER; PROLIFERATION; TARGETED CANCER THERAPY;

CELL DEATH; CHEMOTHERAPY; DRUG PRODUCTS; ENZYME INHIBITION; MOLECULES; NANOPARTICLES; NUCLEIC ACIDS; TOXICITY; TUMORS;

GENE THERAPY;

CALCIUM PHOSPHATE; GEMCITABINE; GEMCITABINE MONOPHOSPHATE; LIPID; MYC PROTEIN; NANOCARRIER; NUCLEOSIDE ANALOG; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH;

MUS MUSCULUS;

APOPTOSIS; C-MYC SIRNA; CALCIUM PHOSPHATE NANOPARTICLE; GEMCITABINE MONOPHOSPHATE; PROLIFERATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM PHOSPHATES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; PROTO-ONCOGENE PROTEINS C-MYB; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881670536     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.050     Document Type: Article

References (22)

1. de Nigris F., Balestrieri M.L., Napoli C. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle 2006, 5(15):1621-1628.
2. Dang C.V. MYC on the path to cancer. Cell 2012, 149(1):22-35.
3. Toyoshima M., Howie H.L., Imakura M., Walsh R.M., Annis J.E., Chang A.N., et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A 2012, 109(24):9545-9550.
4. Zhang Y., Kim W.Y., Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013, 34(13):3447-3458.
5. Oguri T., Achiwa H., Sato S., Bseeho Y., Takano Y., Miyazaki M., et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006, 5(7):1800-1806.
6. Zhang Y., Satterlee A., Huang L. Invivo gene delivery by nonviral vectors: overcoming hurdles?. Mol Ther 2012, 20(7):1298-1304.
7. Banerjee R., Tyagi P., Li S., Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004, 112(4):693-700.
8. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. JControl Release 2012, 158(1):108-114.
9. Zhang Y., Wang X., Wang J., Zhang X., Zhang Q. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharm Res 2011, 28(5):1167-1178.
10. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. JControl Release 2006, 114(1):100-109.
11. Gong H.T., Sun L., Ren X.J., Liu L., Han X.F. Influence of gemcitabine on expression of C-myc gene and its apoptosis-inducing effect on HL-60 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18(2):317-320.
12. Chaitanya G.V., Steven A.J., Babu P.P. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010, 8:31.
13. Boulares A.H., Yakovlev A.G., Ivanova V., Stoica B.A., Wang G., Lyer S., et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. JBiol Chem 1999, 274(33):22932-22940.
14. Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012, 18(20):5546-5553.
15. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1(2):323-334.
16. Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., Culp H.W. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992, 20(6):849-855.
17. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002, 16(19):2530-2543.
18. Soucek L., Evan G.I. The ups and downs of Myc biology. Curr Opin Genet Dev 2010, 20(1):91-95.
19. Kabilova T.O., Chernolovskaya E.L., Vladimirova A.V., Vlassov V.V. Inhibition of human carcinoma and neuroblastoma cell proliferation by anti-c-myc siRNA. Oligonucleotides 2006, 16(1):15-25.
20. Wang Y.H., Liu S., Zhang G., Zhou C.Q., Zhu H.X., Zhou X.B., et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth invitro and invivo. Breast Cancer Res 2005, 7(2):R220-R228.
21. Wang Z., Rao D.D., Senzer N., Nemunaitis J. RNA interference and cancer therapy. Pharm Res 2011, 28(12):2983-2995.
22. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35(18):5616-5623.